Skip to content


Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More


As part of our on-going member support, we are introducing a new website feature to help with common practice management challenges. We welcome your input with questions or challenges you would like to address. Read More


CMS to Provide Advanced Payments to Those Affected by the Change Healthcare Cyberattack

On Saturday, March 9, the Centers for Medicare & Medicaid Services (CMS) released a statement…

Read more

Policy Update: State of the Union Address, Budget Updates

President Biden’s State of the Union Address State of the Union Transcript State of the Union Video…

Read more

Medicare Physician Payment

AMA Advocacy Update The House of Representatives voted 339-85 on March 6 to pass the…

Read more

Upcoming Dates

04/01/24: Fellow Exam Application Deadline
Learn more

06/01/24: Research Grant Cycle
Learn more

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more


AAOA Basic Course

Join us from July 25-27 at the hybrid 2024 AAOA Basic Course. As a hybrid course, we are excited to offer both live in-person and virtual participation. The course content will be accessible for over 90 days to help you maximize value. Register Today 


For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More


Available Now


IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Register

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More and Register 

2025 AAOA Advanced Course in Allergy & Immunology - Hybrid
March 27-29, 2025
The Hythe, Vail, CO
Book Your Room

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Release October 1, 2024

News and Updates

Things to Do, Shows to See While in Las Vegas in November! 

November 5, 9-12 – Mystère by Cirque du Soleil at Mystère Theatre, Treasure Island –…

Read more

CEO Update, April 2024

I am writing this with The Beatles, “Here Comes the Sun,” streaming in the background.…

Read more
College Allergy Symptoms Treatment Back to Shcool


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>



By Anna Butrymowicz, MD

Allergy Immunotherapy (AIT) is an option for patients with allergic rhinitis (AR), allergic asthma and atopic dermatitis.  In the United States, AIT is offered in two forms, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) via tablet or drop.  The choice to pursue AIT is one that should be made after thorough discussion with your Otolaryngologist and is normally considered in patients with the above diagnoses who have failed to improve with medical management or cannot tolerate medical management, and avoidance of known allergens is not possible.  When deciding between form of AIT (SLIT vs SCIT), a number of things should be considered, including efficacy, cost, compliance, and safety.  

Efficacy: the jury is still out.  While large Cochrane reviews suggest superiority of SCIT, there are only a few randomized control trials, and these head to head analyses show equivalent benefit in regard to symptom control and medication use (with exception of 1 RTC which shows superiority of SCIT).  

Cost: This question is addressed directly in the article Hidden Costs of AIT. Overall, aqueous SLIT is considered off label by the FDA and incurs out of pocket costs.  The direct cost of SLIT tablets or co-pays for SCIT depend on insurance coverage.  There is also indirect cost to parking, travel time, missed work/school when pursuing SCIT.  

Compliance: It seems reasonable to assume that patients would be more compliant with medication they could administer at home, like SLIT, but studies show conflicting evidence, some with higher compliance with SCIT, other with higher compliance with SLIT.  Like with every other broad characterization, we have to keep individual patient characteristics/goals in mind, and tailor each treatment plan to the patient.  

Safety: SLIT has a superior safety profile, with no history of reported fatalities and a rare incidence of anaphylaxis.  In general, SCIT is well tolerated, but there have been reported fatalities and the incidence of anaphylaxis is higher.  

Generally, these are the main factors we should consider when discussing AIT with our patients, but this is not a comprehensive list.  And while SCIT and SLIT are the forms of AIT offered in the United States, the field of Otolaryngic Allergy continues to innovate, and we may see new options in the future.  Stay tuned! 

Back To Top